[Hemophilia--present and past].
Through a research of existing literature, the clinical manifestion, diagnosis and treatment of hemophilia A and B are described. This article reviews the recent progress of coagulation factor VIII and IX products, and the efficiency of bypass therapy with rFVIIa, etc., to induce immune tolerance induction in congenital hemophilia with inhibitors and acquired hemophilia. In the future, an explanation of the mechanism and prophylaxy of inhibitors and the progress of genetic therapy are expected.
Terada
Hideo
H
Showa University.
D000328:Adult; D005169:Factor VIII / Q000627:therapeutic use; D015942:Factor VIIa / Q000627:therapeutic use; D015316:Genetic Therapy; D006467:Hemophilia A / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D002836:Hemophilia B / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D007108:Immune Tolerance; D008297:Male; D011379:Prognosis; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D005169:Factor VIII; D015942:Factor VIIa